These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30588029)

  • 1. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
    Zhang Y; He B; Zhou D; Li M; Hu C
    Onco Targets Ther; 2019; 12():51-56. PubMed ID: 30588029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
    Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
    Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
    Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
    J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Pisapia P; Rocco D; Pepe F; De Luca C; Battiloro C; Smeraglio R; Cieri M; Bellevicine C; Troncone G; Malapelle U
    Transl Cancer Res; 2019 Jan; 8(Suppl 1):S64-S69. PubMed ID: 35117065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib as a Potential Therapeutic Option for Patients With NSCLC With
    Wei Y; Jiang B; Liu S; Zhang Z; Fang W; Yang Y; Li X; Zhao J; Zhao H
    JTO Clin Res Rep; 2021 Jul; 2(7):100193. PubMed ID: 34590038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
    Saad N; Poudel A; Basnet A; Gajra A
    Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Observational Study of Acquired
    Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
    Front Oncol; 2020; 10():1481. PubMed ID: 33014788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary resistance to osimertinib despite acquired
    Chang LK; Chang YL; Shih JY
    Respirol Case Rep; 2020 Mar; 8(2):e00532. PubMed ID: 32042433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.
    Pan G; Chen K; Yu X; Sheng J; Fan Y
    Transl Cancer Res; 2021 Jun; 10(6):2895-2905. PubMed ID: 35116599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Patients with
    Sanchis-Borja M; Guisier F; Swalduz A; Curcio H; Basse V; Maritaz C; Chouaid C; Auliac JB
    Onco Targets Ther; 2024; 17():439-448. PubMed ID: 38836187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
    Zeng Y; Feng Y; Fu G; Jiang J; Liu X; Pan Y; Hu C; Liu X; Wu F
    Front Pharmacol; 2022; 13():838247. PubMed ID: 35462930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating
    Mazza V; Cappuzzo F
    Appl Clin Genet; 2017; 10():49-56. PubMed ID: 28794650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation.
    Chen J; Wu X; Wang J
    Front Oncol; 2022; 12():898586. PubMed ID: 35957876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.
    Shen Q; Qu J; Chen Z; Zhou J
    Front Oncol; 2021; 11():760097. PubMed ID: 34926262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.